

REFERENCES

- Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. *Kidney Int.* 2006;69:33-43.
- Baillie GR. Calcium and phosphorus management in chronic kidney disease: challenges and trends. *Formulary.* 2004;39:358-365.
- Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. *Proc Natl Acad Sci U S A.* 1988;85:3294-3298.
- Bielez B. Emerging role of a phosphatonin in mineral homeostasis and its derangements. *Eur J Clin Invest.* 2006;36(suppl 2):34-42.
- Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. *N Engl J Med.* 2004;350:1516-1525.
- Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int.* 2007;71:438-441.
- Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int.* 2005;68:1815-1824.
- Bringhurst FR, Demay MB, Krane SM, Kronenberg HM. Bone and mineral metabolism in health and disease. In: Kasper DL, Braunwald E, Fauci A, et al, eds. *Harrison's Principles of Internal Medicine.* 16th edition. New York, NY: McGraw-Hill; 2005:2238-2249.
- Brown AJ, Dusso A, Slatopolsky E. Vitamin D. *Am J Physiol.* 1999;277:F157-F175.
- Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca²⁺-sensing receptor from bovine parathyroid. *Nature.* 1993;366:575-580.
- Cannata-Andia JB, Rodriguez-Garcia M. Hyperphosphataemia as a cardiovascular risk factor – how to manage the problem. *Nephrol Dial Transplant.* 2002;17(suppl 11):16-19.
- Chang W, Pratt S, Chen TH, Bourguignon L, Shoback D. Amino acids in the cytoplasmic C terminus of the parathyroid Ca²⁺-sensing receptor mediate efficient cell-surface expression and phospholipase C activation. *J Biol Chem.* 2001;276:44129-44136.

Chen RA, Goodman WG. Role of the calcium-sensing receptor in parathyroid gland physiology. *Am J Physiol Renal Physiol.* 2004;286:F1005-F1011.

Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int.* 2002;62:245-252.

Colloton M, Shatzten E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. *Kidney Int.* 2005;67:467-476.

Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5—achievement of K/DOQI target ranges. *Nephrol Dial Transplant.* 2007;22:1171-1176.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney Int.* 2005;68:1793-1800.

Fehr T, Garzoni D, Staub T, et al. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. *Kidney Blood Press Res.* 2006;29:175-181.

Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. *J Am Soc Nephrol.* 2005;16:210-218.

Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis.* 1998;32(5 suppl 3):S112-S119.

Food and Nutrition Board, Institute of Medicine. *Phosphorus. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride.* Washington DC: National Academy Press; 1997:146-189.

Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. *Nephrol Dial Transplant.* 2002;17:204-207.

Goodman WG. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease? *Curr Opin Nephrol Hypertens.* 2005;14:355-360.

Goodman WG. Calcium and phosphorus metabolism in patients who have chronic kidney disease. *Med Clin North Am.* 2005;89:631-647.

UPDATE ON MINERAL METABOLISM IN CKD: Disease Progression, Cardiovascular Complications, and Clinical Outcomes

Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. *Nephrol Dial Transplant*. 2003;18(suppl 3):iii2-iii8.

Goodman WG. Recent developments in the management of secondary hyperparathyroidism. *Kidney Int*. 2001;59:1187-1201.

Goodman WG, Belin TR, Salusky IB. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. *Kidney Int*. 1996;50:1834-1844.

Healy KD, Vanhooke JL, Prah JM, DeLuca HF. Parathyroid hormone decreases renal vitamin D receptor expression in vivo. *Proc Natl Acad Sci U S A*. 2005;102:4724-4728.

Hoenderop JG, Nilius B, Bindels RJ. Calcium absorption across epithelia. *Physiol Rev*. 2005;85:373-422.

Hutchison AJ, Maes B, Vanwallegem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. *Nephron Clin Pract*. 2006;102:c61-c71.

Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. *Kidney Int*. 2006;70:771-780.

Kos CH, Karaplis AC, Peng JB, et al. The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. *J Clin Invest*. 2003;111:1021-1028.

Kovacs CS, Ho-Pao CL, Hunzelman JL, et al. Regulation of murine fetal-placental calcium metabolism by the calcium-sensing receptor. *J Clin Invest*. 1998;101:2812-2820.

Lambers TT, Bindels RJ, Hoenderop JG. Coordinated control of renal Ca²⁺ handling. *Kidney Int*. 2006;69:650-654.

Lederer E, Ouseph R. Chronic kidney disease. *Am J Kidney Dis*. 2007;49:162-171.

Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. *Kidney Int*. 2007;71:31-38.

Li YC, Amling M, Pirro AE, et al. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. *Endocrinology*. 1998;139:4391-4396.

Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. *J Am Soc Nephrol*. 2006;17:1305-1315.

Locatelli F, Cannata-Andia JB, Druke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. *Nephrol Dial Transplant*. 2002;17:723-731.

Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. *Am J Kidney Dis*. 1997;29:496-502.

Mayer GP, Hurst JG. Sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentration in calves. *Endocrinology*. 1978;102:1036-1042.

Moallem E, Kilav R, Silver J, Naveh-Many T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. *J Biol Chem*. 1998;273:5253-5259.

Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int*. 2005;67:760-771.

Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. *Nephrol Dial Transplant*. 2005;20:2186-2193.

Moe SM. Vascular calcification: hardening of the evidence. *Kidney Int*. 2006;70:1535-1537.

Murray TM, Rao LG, Divieti P and Bringhurst FR. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands. *Endocr Rev*. 2005;26:78-113.

National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis*. 2003;42(4 suppl 3):S1-S201.

National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39(2 suppl 1):S1-S266.

UPDATE ON MINERAL METABOLISM IN CKD: Disease Progression, Cardiovascular Complications, and Clinical Outcomes

Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. *J Pharmacol Exp Ther.* 2004;308:627-635.

Phosphate metabolism. In: *The Merck Manual of Diagnosis and Therapy*. Section 2. Chapter 12.

Razzaque MS, St-Arnaud R, Taguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. *Nephrol Dial Transplant.* 2005;20:2032-2035.

Renagel® (sevelamer hydrochloride) [package insert]. Cambridge, Mass: Genzyme Corporation; 2004.

Richards ML, Wormuth J, Bingener J, Sirinek K. Parathyroidectomy in secondary hyperparathyroidism: is there an optimal operative management? *Surgery.* 2006;139:174-180.

Ritz E. The clinical management of hyperphosphatemia. *J Nephrol.* 2005;18:221-228.

Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. *Am J Physiol Renal Physiol.* 2005;288:F253-F264.

Shanahan CM. Vascular calcification. *Curr Opin Nephrol Hypertens.* 2005;14:361-367.

Skorecki K, et al. *Harrison's Principles of Internal Medicine*. 15th ed. 2001:1551-1562.

Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. *Am J Kidney Dis.* 2001;37(1 suppl 2):S54-S57.

Sprague SM, Llach F, Amdahl M, Taccetta C, Battle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. *Kidney Int.* 2003;63:1483-1490.

Steddon SJ, Cunningham J. Calcimimetics and calcilytics—fooling the calcium receptor. *Lancet.* 2005;365:2237-2239.

Takeda E, Taketani Y, Morita K, et al. Molecular mechanisms of mammalian inorganic phosphate homeostasis. *Adv Enzyme Regul.* 2000;40:285-302.

Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol.* 2005;16:1115-1125.



Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. *Kidney Int.* 2006;70:1858-1865.

Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. *Crit Rev Clin Lab Sci.* 2005;42:35-70.

Vieira JGH, Kunii I, Nishida S. Evolution of PTH assays. *Arq Bras Endocrinol Metab.* 2006;50:621-627.